Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19345232rdf:typepubmed:Citationlld:pubmed
pubmed-article:19345232lifeskim:mentionsumls-concept:C0014257lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C0007428lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C0068355lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C0439857lld:lifeskim
pubmed-article:19345232lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:19345232pubmed:issue1lld:pubmed
pubmed-article:19345232pubmed:dateCreated2009-6-15lld:pubmed
pubmed-article:19345232pubmed:abstractTextCathepsin L is a cysteine protease that can generate endogenous endostatin in vascular and epithelial basement membranes and importantly participates in a variety of pathophysiological processes. The present study was designed to determine whether this cathepsin L-derived endogenous endostatin alters endothelium-dependent vasodilator responses in coronary arteries via NAD(P)H oxidase activation. In isolated and perfused small bovine coronary arteries, administration of cathepsin L (200 ng/ml) markedly attenuated endothelium-dependent vasodilator responses to bradykinin or A23187 by 56.16+/-9.58% and 68.95+/-10.32%, respectively. This inhibitory effect of cathepsin L on endothelium-dependent vasodilator responses could be significantly reversed by pre-incubation of the arteries with O(2)(-) scavenger, Tiron, or neutralizing anti-endostatin antibody. By fluorescent ELISA assay, cathepsin L dose-dependently increased endostatin production in coronary arteries. In situ high-speed dual wavelength switching fluorescent microscopic imaging showed that cathepsin L decreased bradykinin- and A23187-induced NO levels in the intact endothelium, but it had no effect on Ca(2+) response to these vasodilators. This cathepsin L-induced reduction of NO was restored by the pretreatment of an anti-endostatin antibody. Electron spin resonance (ESR) analysis demonstrated that cathepsin L increased O(2)(-) production which could be markedly attenuated by the NAD(P)H oxidase inhibitors, apocynin or anti-endostatin antibody. It is concluded that endostatin could be endogenously produced in coronary arteries when cathepsin L is increased and that this cathepsin L-derived endostatin, if excessive, may result in endothelial dysfunction through enhanced production of O(2)(-) due to NAD(P)H oxidase activation.lld:pubmed
pubmed-article:19345232pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:languageenglld:pubmed
pubmed-article:19345232pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:citationSubsetIMlld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19345232pubmed:statusMEDLINElld:pubmed
pubmed-article:19345232pubmed:monthJunlld:pubmed
pubmed-article:19345232pubmed:issn1095-9319lld:pubmed
pubmed-article:19345232pubmed:authorpubmed-author:ZhangFanFlld:pubmed
pubmed-article:19345232pubmed:authorpubmed-author:ZhangYangYlld:pubmed
pubmed-article:19345232pubmed:authorpubmed-author:LiPin-LanPLlld:pubmed
pubmed-article:19345232pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19345232pubmed:volume78lld:pubmed
pubmed-article:19345232pubmed:ownerNLMlld:pubmed
pubmed-article:19345232pubmed:authorsCompleteYlld:pubmed
pubmed-article:19345232pubmed:pagination45-50lld:pubmed
pubmed-article:19345232pubmed:dateRevised2010-12-28lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:meshHeadingpubmed-meshheading:19345232...lld:pubmed
pubmed-article:19345232pubmed:year2009lld:pubmed
pubmed-article:19345232pubmed:articleTitleDependence of cathepsin L-induced coronary endothelial dysfunction upon activation of NAD(P)H oxidase.lld:pubmed
pubmed-article:19345232pubmed:affiliationDepartment of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, 410 N 12th, Richmond, VA 23298, USA.lld:pubmed
pubmed-article:19345232pubmed:publicationTypeJournal Articlelld:pubmed